Perrigo (PRGO) Gets Final FDA Approval for Generic Prevacid Caps (NVS)
Tweet
Share
E-mailGet Alerts PRGO Hot Sheet
Join SI Premium – FREE
Perrigo Company (Nasdaq: PRGO) has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application (ANDA) for Lansoprazole capsules (15 mg). Shipments of product to customers have already begun.
This new product for the U.S. store brand market is bioequivalent to Novartis' (NYSE: NVS) Prevacid 24HR capsules (15 mg) and is indicated for the treatment of frequent heartburn, which occurs two or more days in a week. Sales for Prevacid OTC were approximately $220 million.
This new product for the U.S. store brand market is bioequivalent to Novartis' (NYSE: NVS) Prevacid 24HR capsules (15 mg) and is indicated for the treatment of frequent heartburn, which occurs two or more days in a week. Sales for Prevacid OTC were approximately $220 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AstraZeneca's Tezspire meets endpoints in esophagitis trial
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Baidu to gain dual-primary listing status in Hong Kong on Sept. 1
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
